A study presented at the European Association for the Study of Diabetes Annual Meeting found that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduced the incidence of new-onset type 2 diabetes by 25% in patients with heart failure with mildly reduced or preserved ejection fraction. The FINEARTS-HF trial also showed that finerenone reduced worsening heart failure events and cardiovascular death. The drug was found to be effective in patients with and without diabetes, with fewer instances of hyperkalemia compared to placebo. The results suggest that finerenone may be a beneficial treatment option for patients with heart failure in preventing diabetes and improving heart health.
Source link
Finerenone Reduces T2D Onset in HF With Preserved EF
